These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 32741645)
1. The Relationship Between Timing of Initiation on a Glucagon-like Peptide-1 Receptor Agonist and Glycosylated Hemoglobin Values Among Patients With Type 2 Diabetes. Boye KS; Mody R; Lage MJ; Malik RE Clin Ther; 2020 Sep; 42(9):1812-1817.e2. PubMed ID: 32741645 [TBL] [Abstract][Full Text] [Related]
2. Characteristics Associated with the Choice of First Injectable Therapy Among US Patients With Type 2 Diabetes. Yu M; Mody R; Landó LF; Shui A; Kallenbach L; Slipski L; de Oliveira CP Clin Ther; 2017 Dec; 39(12):2399-2408. PubMed ID: 29196084 [TBL] [Abstract][Full Text] [Related]
3. Effectiveness, treatment durability, and treatment costs of canagliflozin and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes in the USA. Singhal M; Tan H; Coleman CI; Han M; Nguyen C; Ingham M BMJ Open Diabetes Res Care; 2019; 7(1):e000704. PubMed ID: 31798890 [TBL] [Abstract][Full Text] [Related]
4. Insulin-glucagon-like peptide-1 receptor agonist relay and glucagon-like peptide-1 receptor agonist first regimens in individuals with type 2 diabetes: A randomized, open-label trial study. Takeshita Y; Kita Y; Tanaka T; Goto H; Nakano Y; Teramura C; Enyama Y; Takamura T; J Diabetes Investig; 2022 Jun; 13(6):965-974. PubMed ID: 35034428 [TBL] [Abstract][Full Text] [Related]
6. HBA1C CONTROL AND COST-EFFECTIVENESS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INITIATED ON CANAGLIFLOZIN OR A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST IN A REAL-WORLD SETTING. Wysham CH; Pilon D; Ingham M; Lafeuille MH; Emond B; Kamstra R; Pfeifer M; Lefebvre P Endocr Pract; 2018 Mar; 24(3):273-287. PubMed ID: 29547044 [TBL] [Abstract][Full Text] [Related]
7. Timing of GLP-1 Receptor Agonist Initiation for Treatment of Type 2 Diabetes in the UK. Boye KS; Stein D; Matza LS; Jordan J; Yu R; Norrbacka K; Hassan SW; García-Pérez LE Drugs R D; 2019 Jun; 19(2):213-225. PubMed ID: 31115873 [TBL] [Abstract][Full Text] [Related]
8. Adherence to NICE guidance on glucagon-like peptide-1 receptor agonists among patients with type 2 diabetes mellitus: an evaluation using the Clinical Practice Research Datalink. Jameson K; D'Oca K; Leigh P; Murray-Thomas T Curr Med Res Opin; 2016; 32(1):49-60. PubMed ID: 26428701 [TBL] [Abstract][Full Text] [Related]
9. Real-world impact on monthly glucose-lowering medication cost, HbA Rose TN; Jacobs ML; Reid DJ; Bouwmeester CJ; Conley MP; Fatehi B; Matta TM; Barr JT J Am Pharm Assoc (2003); 2020; 60(1):31-38.e1. PubMed ID: 31611005 [TBL] [Abstract][Full Text] [Related]
10. Comparison of Characteristics Between Chinese Patients Taking Glucagon-like Peptide 1 Receptor Agonists and Insulin: A Cross-sectional Database Analysis. Wang K; Chen Y; Strizek A; Boye K; Gu L; Liu Y; Qu S Clin Ther; 2019 Oct; 41(10):2057-2065. PubMed ID: 31514971 [TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics, treatment patterns, and persistence in individuals with type 2 diabetes initiating a glucagon-like peptide-1 receptor agonist: A retrospective analysis of the Diabetes Prospective Follow-Up Registry. Jung H; Tittel SR; Schloot NC; Heitmann E; Otto T; Lebrec J; Pavel M; Lanzinger S Diabetes Obes Metab; 2023 Jul; 25(7):1813-1822. PubMed ID: 36855221 [TBL] [Abstract][Full Text] [Related]
12. Quality goal attainment and maintenance in patients with type II diabetes mellitus initiated on canagliflozin or a glucagon-like peptide-1 receptor agonist in an actual practice setting. Wysham CH; Pilon D; Ingham M; Lafeuille MH; Emond B; Kamstra R; Pfeifer M; Lefebvre P Curr Med Res Opin; 2018 Jun; 34(6):1125-1133. PubMed ID: 29557199 [TBL] [Abstract][Full Text] [Related]
13. Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with statins. Hasegawa Y; Hori M; Nakagami T; Harada-Shiba M; Uchigata Y J Clin Lipidol; 2018; 12(1):62-69.e1. PubMed ID: 29217412 [TBL] [Abstract][Full Text] [Related]
14. Initiating GLP-1 Therapy in Combination with FreeStyle Libre Provides Greater Benefit Compared with GLP-1 Therapy Alone. Wright EE; Roberts GJ; Chuang JS; Nabutovsky Y; Virdi N; Miller E Diabetes Technol Ther; 2024 Oct; 26(10):754-762. PubMed ID: 38669474 [No Abstract] [Full Text] [Related]
15. The Effect of Early Response to GLP-1 RA Therapy on Long-Term Adherence and Persistence Among Type 2 Diabetes Patients in the United States. Durden E; Liang M; Fowler R; Panton UH; Mocevic E J Manag Care Spec Pharm; 2019 Jun; 25(6):669-680. PubMed ID: 30896359 [TBL] [Abstract][Full Text] [Related]
16. Switching to iGlarLixi versus continuation of a daily or weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) in insufficiently controlled type 2 diabetes: A LixiLan-G trial subgroup analysis by HbA1c and GLP-1 RA use at screening. Rosenstock J; Blonde L; Aroda VR; Frias J; Souhami E; Ji C; Niemoeller E; Del Prato S Diabetes Obes Metab; 2021 Jun; 23(6):1331-1341. PubMed ID: 33565209 [TBL] [Abstract][Full Text] [Related]
17. De-intensification of basal-bolus insulin regimen after initiation of a GLP-1 RA improves glycaemic control and promotes weight loss in subjects with type 2 diabetes. Falcetta P; Nicolì F; Citro F; Ciccarone A; Garofolo M; Del Prato S; Bianchi C Acta Diabetol; 2023 Jan; 60(1):53-60. PubMed ID: 36166172 [TBL] [Abstract][Full Text] [Related]
18. Real world use of tirzepatide in the treatment of type 2 diabetes in an Arab population. Buckley A; Suliman S; Allum M; Mohammed N; Lessan N; le Roux CW; Suliman M Diabetes Obes Metab; 2024 Aug; 26(8):3381-3391. PubMed ID: 38783825 [TBL] [Abstract][Full Text] [Related]
19. Glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes:real-world evidence from a Mediterranean area. Mata-Cases M; Franch-Nadal J; Ortega E; Real J; Gratacòs M; Vlacho B; Mauricio D Curr Med Res Opin; 2019 Oct; 35(10):1735-1744. PubMed ID: 31081693 [No Abstract] [Full Text] [Related]
20. Addition of or switch to insulin therapy in people treated with glucagon-like peptide-1 receptor agonists: A real-world study in 66 583 patients. Montvida O; Klein K; Kumar S; Khunti K; Paul SK Diabetes Obes Metab; 2017 Jan; 19(1):108-117. PubMed ID: 27629433 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]